Genetic tests for people with autism are far from routine and don’t always yield results, but the information they offer can change lives.

After the presentation of more than 14,000 abstracts over five days, the Society for Neuroscience annual meeting in San Diego ended last week.

Modified stem cells show promise for delivering gene-based therapies to individuals with Angelman syndrome.

A new protocol enables researchers to rigorously test drugs for Angelman syndrome in mice.

It is not a matter of whether there will be clinical trials of genetic therapy for Angelman syndrome, but when.

Compounds that mimic a cancer drug restore expression of the key gene mutated in Angelman syndrome, a condition related to autism.

The international manual of conditions now includes a diagnostic code for Angelman syndrome — which may enable scientists to systematically collect information about the syndrome.

Sleep problems in autism may stem from the same biological changes that underlie the core features of the condition.

Exposure to certain types of light at night may exacerbate sleep issues among people with autism.

Introducing the gene UBE3A into neurons that dampen brain activity prevents seizures in a mouse model of Angelman syndrome.